Synopsis
Synopsis
0
KDMF
0
VMF
0
Australia
Annual Reports
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 4-amino-5-chloro-n-(2-(diethylamino)ethyl)-2-methoxybenzamide
2. Cerucal
3. Dihydrochloride, Metoclopramide
4. Hydrochloride, Metoclopramide
5. Maxolon
6. Metaclopramide
7. Metoclopramide
8. Metoclopramide Dihydrochloride
9. Metoclopramide Monohydrochloride
10. Metoclopramide Monohydrochloride, Monohydrate
11. Monohydrochloride, Metoclopramide
12. Primperan
13. Reglan
14. Rimetin
1. 7232-21-5
2. Maxolon
3. Metoclopramide Hcl
4. Metoclopramide Monohydrochloride
5. Cerucal
6. Paspertin
7. Clopra
8. Reglan
9. 4-amino-5-chloro-n-(2-(diethylamino)ethyl)-2-methoxybenzamide Hydrochloride
10. Metozolv
11. Metozolv Odt
12. Metoclopramide Hydrochloride Anhydrous
13. 7b1qzy5swz
14. Metoclopramide (hydrochloride)
15. Mls000069667
16. 4-amino-5-chloro-n-[2-(diethylamino)ethyl]-2-methoxybenzamide;hydrochloride
17. Benzamide, 4-amino-5-chloro-n-(2-(diethylamino)ethyl)-2-methoxy-, Monohydrochloride
18. Nsc-354467
19. Rimetin
20. Smr000058471
21. 4-amino-5-chloro-n-(2-(diethylamino)ethyl)-o-anisamide Hydrochloride
22. Primperan (tablet)
23. Metoclopramide Hydrochloride 100 Microg/ml In Acetonitrile
24. Metoclopramide Intensol
25. Reglan Odt
26. Ccris 7142
27. Sr-01000000165
28. Einecs 230-634-5
29. Unii-7b1qzy5swz
30. Nsc 354467
31. 4-amino-5-chloro-n-[2-(diethylamino)ethyl]-o-anisamide Hydrochloride
32. Prestwick_332
33. 4-amino-5-chloro-n-(2-diethylaminoethyl)-2-methoxy-benzamide
34. Mfcd00058011
35. Metoclopramidehcl
36. Opera_id_1671
37. Mls001074186
38. Mls002222202
39. O-anisamide, Monohydrochloride
40. Schembl205200
41. Spectrum1500410
42. Chembl1256771
43. Dtxsid10964306
44. Hms1568j19
45. Hms1920n15
46. Metoclopramide Hydrochloride, Solid
47. Pharmakon1600-01500410
48. Bcp28471
49. Tox21_500762
50. Nsc354467
51. Nsc757117
52. 4-amino-5-chloro-n-(2-diethylaminoethyl)-2-methoxybenzamide Hydrochloride
53. Akos015889947
54. O-anisamide, 4-amino-5-chloro-n-(2-(diethylamino)ethyl)-, Monohydrochloride
55. Ccg-212697
56. Hs-0006
57. Lp00762
58. Nc00519
59. 4-amino-5-chloro-n-(2-(diethylamino)ethyl)-2-methoxybenzamide Monohydrochloride
60. Ncgc00094102-01
61. Ncgc00094102-02
62. Ncgc00094102-03
63. Ncgc00094102-04
64. Ncgc00094102-05
65. Ncgc00261447-01
66. Wln: 2n2&2mvr Dz Cg Fo1 &gh
67. Eu-0100762
68. Ft-0657870
69. Ft-0672375
70. S4289
71. Sw196611-3
72. Vu0239518-5
73. A14247
74. M 0763
75. A923754
76. Sr-01000000165-2
77. Sr-01000000165-7
78. Q27267998
79. 4-amino-5-chloro-n-(2-diethylaminoethyl)-2-methoxybenzamide Hcl
80. 4-amino-5-chloro-n-(2-(diethylamino)ethyl)-o-anisamidmonohydrochloride
81. 4-amino-5-chloro-n-(2-(diethylamino)ethyl)-o-anisamide Monohydrochloride
82. Benzamide, 4-amino-5-chloro-n-(2-(diethylamino)ethyl)-2-methoxy-, Monohydrochloride (9ci)
83. Benzamide, 4-amino-5-chloro-n-[2-(diethylamino)ethyl]-2-methoxy-, Hydrochloride (1:1)
| Molecular Weight | 336.3 g/mol |
|---|---|
| Molecular Formula | C14H23Cl2N3O2 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 7 |
| Exact Mass | 335.1167324 g/mol |
| Monoisotopic Mass | 335.1167324 g/mol |
| Topological Polar Surface Area | 67.6 Ų |
| Heavy Atom Count | 21 |
| Formal Charge | 0 |
| Complexity | 300 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Metoclopramide hydrochloride |
| Drug Label | Metoclopramide hydrochloride is a white or practically white, crystalline, odorless or practically odorless powder. It is very soluble in water, freely soluble in alcohol, sparingly soluble in chloroform, practically insoluble in ether. Chemically it... |
| Active Ingredient | Metoclopramide hydrochloride |
| Dosage Form | Tablet; Injectable; Tablet, orally disintegrating; Solution |
| Route | Injection; Oral |
| Strength | eq 5mg base; eq 5mg base/5ml; eq 5mg base/ml; eq 10mg base |
| Market Status | Prescription |
| Company | Vintage Pharms; Wockhardt; Silarx; Ani Pharms; Hospira; Teva; Pharm Assoc; Teva Pharms Usa; Northstar Hlthcare; Par Pharm; Novel Labs; Watson Labs; Vistapharm; Ipca Labs; Mutual Pharm; Bd Rx |
| 2 of 4 | |
|---|---|
| Drug Name | Metozolv odt |
| PubMed Health | Metoclopramide |
| Drug Classes | Antiemetic, Diagnostic Agent, Stimulant, Gastrointestinal |
| Drug Label | METOZOLV ODT is an orally disintegrating tablet formulation of metoclopramide hydrochloride. The 5 mg strength is a round white tablet debossed on one side with a 5 and plain on the other side; it is comprised of 5 mg metoclopramide (as 5.91... |
| Active Ingredient | Metoclopramide hydrochloride |
| Dosage Form | Tablet, orally disintegrating |
| Route | Oral |
| Strength | eq 5mg base |
| Market Status | Prescription |
| Company | Salix Pharms |
| 3 of 4 | |
|---|---|
| Drug Name | Metoclopramide hydrochloride |
| Drug Label | Metoclopramide hydrochloride is a white or practically white, crystalline, odorless or practically odorless powder. It is very soluble in water, freely soluble in alcohol, sparingly soluble in chloroform, practically insoluble in ether. Chemically it... |
| Active Ingredient | Metoclopramide hydrochloride |
| Dosage Form | Tablet; Injectable; Tablet, orally disintegrating; Solution |
| Route | Injection; Oral |
| Strength | eq 5mg base; eq 5mg base/5ml; eq 5mg base/ml; eq 10mg base |
| Market Status | Prescription |
| Company | Vintage Pharms; Wockhardt; Silarx; Ani Pharms; Hospira; Teva; Pharm Assoc; Teva Pharms Usa; Northstar Hlthcare; Par Pharm; Novel Labs; Watson Labs; Vistapharm; Ipca Labs; Mutual Pharm; Bd Rx |
| 4 of 4 | |
|---|---|
| Drug Name | Metozolv odt |
| PubMed Health | Metoclopramide |
| Drug Classes | Antiemetic, Diagnostic Agent, Stimulant, Gastrointestinal |
| Drug Label | METOZOLV ODT is an orally disintegrating tablet formulation of metoclopramide hydrochloride. The 5 mg strength is a round white tablet debossed on one side with a 5 and plain on the other side; it is comprised of 5 mg metoclopramide (as 5.91... |
| Active Ingredient | Metoclopramide hydrochloride |
| Dosage Form | Tablet, orally disintegrating |
| Route | Oral |
| Strength | eq 5mg base |
| Market Status | Prescription |
| Company | Salix Pharms |
Dopamine D2 Receptor Antagonists
Compounds and drugs that bind to and inhibit or block the activation of DOPAMINE D2 RECEPTORS. (See all compounds classified as Dopamine D2 Receptor Antagonists.)
Antiemetics
Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)
Metoclopramide Hydrochloride BP/USP
Date of Issue : 2022-08-16
Valid Till : 2025-08-15
Written Confirmation Number : WC-0258n
Address of the Firm : Phase III, Gangyal Jammu (J&K)

Metoclopramide Hydrochloride BP/USP/PH. Eur
Date of Issue : 2025-06-19
Valid Till : 2028-07-02
Written Confirmation Number : WC-0091
Address of the Firm : P.O. Sejavta, District -Ratlam, (M.P.)-457001, India

Metoclopramide Hydrochloride IP/BP/USP/Ph.Eur
Date of Issue : 2024-06-10
Valid Till : 2027-06-09
Written Confirmation Number : WC-0583
Address of the Firm : Plot No. -16 -22, Industrial Area No.01, A.B. Road, District - Dewas, Madhya Pra...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Through the licensing deal for Metoclopramide HCl, targeting the Serotonin 4 receptor, the agreement aims to address nausea.
Lead Product(s): Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Plasil
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 18, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Lupin Ltd
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lupin Signs Licensing Deal with Neopharmed for Plasil in Philippines, Brazil
Details : Through the licensing deal for Metoclopramide HCl, targeting the Serotonin 4 receptor, the agreement aims to address nausea.
Product Name : Plasil
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 18, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Reglan-Generic (metoclopramide) is a 5-HT3a and D2 receptor inhibitor small molecule drug candidate indicated for the treatment of diabetic gastroparesis, & prevention of nausea and vomiting.
Lead Product(s): Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Reglan-Generic
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Avenacy Announces Launch of Metoclopramide Injection, USP in the U.S. Market
Details : Reglan-Generic (metoclopramide) is a 5-HT3a and D2 receptor inhibitor small molecule drug candidate indicated for the treatment of diabetic gastroparesis, & prevention of nausea and vomiting.
Product Name : Reglan-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 16, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Gimoti (metoclopramide) increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and intestinal transit.
Lead Product(s): Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Gimoti
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 20, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gimoti (metoclopramide) increases the tone and amplitude of gastric (especially antral) contractions, relaxes the pyloric sphincter and the duodenal bulb, and increases peristalsis of the duodenum and jejunum resulting in accelerated gastric emptying and...
Product Name : Gimoti
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 20, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Gimoti (metoclopramide) nasal spray is a dopamine receptor antagonist to treat nausea and vomiting in patients with gastroesophageal reflux disease or diabetic gastroparesis by increasing movements or contractions of the stomach and intestines.
Lead Product(s): Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Gimoti
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 19, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gimoti (metoclopramide) nasal spray is a dopamine receptor antagonist to treat nausea and vomiting in patients with gastroesophageal reflux disease or diabetic gastroparesis by increasing movements or contractions of the stomach and intestines.
Product Name : Gimoti
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 19, 2023

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Lead Product(s): Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Gimoti
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 07, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
USPTO Grants New Patent to Evoke Pharma Covering the Usage of GIMOTI® To Treat Moderate to Severe...
Details : The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Product Name : Gimoti
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 07, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
GIMOTI (metoclopramide) is a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder in which the stomach takes too long to empty its contents.
Lead Product(s): Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Gimoti
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 30, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GIMOTI (metoclopramide) is a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder in which the stomach takes too long to empty ...
Product Name : Gimoti
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 30, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
GIMOTI is the first and only FDA-approved novel nasal formulation of metoclopramide that is commercially available and specifically designed to deliver a non-oral dose of metoclopramide for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Lead Product(s): Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Gimoti
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 30, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GIMOTI is the first and only FDA-approved novel nasal formulation of metoclopramide that is commercially available and specifically designed to deliver a non-oral dose of metoclopramide for the relief of symptoms in adults with acute and recurrent diabet...
Product Name : Gimoti
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 30, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
GIMOTI (metoclopramide) is first and only FDA-approved nasal formulation of metoclopramide that is commercially available and specifically designed to deliver non-oral dose of metoclopramide for relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Lead Product(s): Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Gimoti
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 20, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evoke Pharma Receives Notice of Allowance from USPTO for a Patent Related to GIMOTI
Details : GIMOTI (metoclopramide) is first and only FDA-approved nasal formulation of metoclopramide that is commercially available and specifically designed to deliver non-oral dose of metoclopramide for relief of symptoms in adults with acute and recurrent diabe...
Product Name : Gimoti
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 20, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
GIMOTI, a nasal spray formulation of metoclopramide, is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Lead Product(s): Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Gimoti
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 06, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evoke Pharma Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use
Details : GIMOTI, a nasal spray formulation of metoclopramide, is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Product Name : Gimoti
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 06, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Gimoti (metoclopramide) nasal spray, is a dopamine-2 (D2) antagonist is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Lead Product(s): Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area: Gastroenterology Brand Name: Gimoti
Study Phase: Approved FDFProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 15, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Metoclopramide Hydrochloride,Inapplicable
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evoke Pharma Announces Approval of GIMOTI to Florida State Medicaid Program
Details : Gimoti (metoclopramide) nasal spray, is a dopamine-2 (D2) antagonist is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
Product Name : Gimoti
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 15, 2022

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Primperan
Dosage Form : Tablet
Dosage Strength : 10MG
Packaging :
Approval Date : 01-07-1965
Application Number : 41446
Regulatory Info : Authorized
Registration Country : Spain
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Primperan
Dosage Form : Injectable Solution
Dosage Strength : 10MG
Packaging :
Approval Date : 01-12-1964
Application Number : 40256
Regulatory Info : Authorized
Registration Country : Spain
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Primperan
Dosage Form : Solution
Dosage Strength : 1MG
Packaging :
Approval Date : 01-12-1964
Application Number : 40257
Regulatory Info : Authorized
Registration Country : Spain
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Primeran
Dosage Form : Injection Solution
Dosage Strength : 5mg/ml
Packaging :
Approval Date : 28-04-1969
Application Number : 28100542968
Regulatory Info : Prescription
Registration Country : Denmark
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info : Deregistered
Registration Country : Sweden
Acetylsalicylate-DL-Lysine; Metoclopramide Hydrochloride Monohydrate
Brand Name : Migpriv
Dosage Form : Oral Solution Powder
Dosage Strength : 900mg;10mg
Packaging :
Approval Date : 28-08-1998
Application Number : 2.00E+13
Regulatory Info : Deregistered
Registration Country : Sweden
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Metoclopramide \"Orion\"
Dosage Form : Film Coated Tablet
Dosage Strength : 10mg
Packaging :
Approval Date : 28-09-2015
Application Number : 28105462814
Regulatory Info : Prescription
Registration Country : Denmark
Regulatory Info :
Registration Country : India
Brand Name : Metoclopramide Hydrochloride
Dosage Form : Tablet
Dosage Strength : 10mg
Packaging : Pack Size 10x10
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name : Metoclopramide Hydrochloride
Dosage Form : Injection
Dosage Strength : 5mg/ml
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : DISCN
Registration Country : USA
Brand Name : METOCLOPRAMIDE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 10MG BASE
Packaging :
Approval Date : 1985-10-17
Application Number : 70581
Regulatory Info : DISCN
Registration Country : USA
Regulatory Info : RX
Registration Country : USA
Brand Name : METOCLOPRAMIDE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 5MG BASE
Packaging :
Approval Date : 2006-08-28
Application Number : 77878
Regulatory Info : RX
Registration Country : USA
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
78
PharmaCompass offers a list of Metoclopramide Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Metoclopramide Hydrochloride manufacturer or Metoclopramide Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Metoclopramide Hydrochloride manufacturer or Metoclopramide Hydrochloride supplier.
A Metoclopramide hydrochloride [USAN:JAN] manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Metoclopramide hydrochloride [USAN:JAN], including repackagers and relabelers. The FDA regulates Metoclopramide hydrochloride [USAN:JAN] manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Metoclopramide hydrochloride [USAN:JAN] API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Metoclopramide hydrochloride [USAN:JAN] manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Metoclopramide hydrochloride [USAN:JAN] supplier is an individual or a company that provides Metoclopramide hydrochloride [USAN:JAN] active pharmaceutical ingredient (API) or Metoclopramide hydrochloride [USAN:JAN] finished formulations upon request. The Metoclopramide hydrochloride [USAN:JAN] suppliers may include Metoclopramide hydrochloride [USAN:JAN] API manufacturers, exporters, distributors and traders.
click here to find a list of Metoclopramide hydrochloride [USAN:JAN] suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Metoclopramide hydrochloride [USAN:JAN] DMF (Drug Master File) is a document detailing the whole manufacturing process of Metoclopramide hydrochloride [USAN:JAN] active pharmaceutical ingredient (API) in detail. Different forms of Metoclopramide hydrochloride [USAN:JAN] DMFs exist exist since differing nations have different regulations, such as Metoclopramide hydrochloride [USAN:JAN] USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Metoclopramide hydrochloride [USAN:JAN] DMF submitted to regulatory agencies in the US is known as a USDMF. Metoclopramide hydrochloride [USAN:JAN] USDMF includes data on Metoclopramide hydrochloride [USAN:JAN]'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Metoclopramide hydrochloride [USAN:JAN] USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Metoclopramide hydrochloride [USAN:JAN] suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Metoclopramide hydrochloride [USAN:JAN] Drug Master File in Japan (Metoclopramide hydrochloride [USAN:JAN] JDMF) empowers Metoclopramide hydrochloride [USAN:JAN] API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Metoclopramide hydrochloride [USAN:JAN] JDMF during the approval evaluation for pharmaceutical products. At the time of Metoclopramide hydrochloride [USAN:JAN] JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Metoclopramide hydrochloride [USAN:JAN] suppliers with JDMF on PharmaCompass.
A Metoclopramide hydrochloride [USAN:JAN] CEP of the European Pharmacopoeia monograph is often referred to as a Metoclopramide hydrochloride [USAN:JAN] Certificate of Suitability (COS). The purpose of a Metoclopramide hydrochloride [USAN:JAN] CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Metoclopramide hydrochloride [USAN:JAN] EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Metoclopramide hydrochloride [USAN:JAN] to their clients by showing that a Metoclopramide hydrochloride [USAN:JAN] CEP has been issued for it. The manufacturer submits a Metoclopramide hydrochloride [USAN:JAN] CEP (COS) as part of the market authorization procedure, and it takes on the role of a Metoclopramide hydrochloride [USAN:JAN] CEP holder for the record. Additionally, the data presented in the Metoclopramide hydrochloride [USAN:JAN] CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Metoclopramide hydrochloride [USAN:JAN] DMF.
A Metoclopramide hydrochloride [USAN:JAN] CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Metoclopramide hydrochloride [USAN:JAN] CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Metoclopramide hydrochloride [USAN:JAN] suppliers with CEP (COS) on PharmaCompass.
A Metoclopramide hydrochloride [USAN:JAN] written confirmation (Metoclopramide hydrochloride [USAN:JAN] WC) is an official document issued by a regulatory agency to a Metoclopramide hydrochloride [USAN:JAN] manufacturer, verifying that the manufacturing facility of a Metoclopramide hydrochloride [USAN:JAN] active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Metoclopramide hydrochloride [USAN:JAN] APIs or Metoclopramide hydrochloride [USAN:JAN] finished pharmaceutical products to another nation, regulatory agencies frequently require a Metoclopramide hydrochloride [USAN:JAN] WC (written confirmation) as part of the regulatory process.
click here to find a list of Metoclopramide hydrochloride [USAN:JAN] suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Metoclopramide hydrochloride [USAN:JAN] as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Metoclopramide hydrochloride [USAN:JAN] API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Metoclopramide hydrochloride [USAN:JAN] as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Metoclopramide hydrochloride [USAN:JAN] and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Metoclopramide hydrochloride [USAN:JAN] NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Metoclopramide hydrochloride [USAN:JAN] suppliers with NDC on PharmaCompass.
Metoclopramide hydrochloride [USAN:JAN] Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Metoclopramide hydrochloride [USAN:JAN] GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Metoclopramide hydrochloride [USAN:JAN] GMP manufacturer or Metoclopramide hydrochloride [USAN:JAN] GMP API supplier for your needs.
A Metoclopramide hydrochloride [USAN:JAN] CoA (Certificate of Analysis) is a formal document that attests to Metoclopramide hydrochloride [USAN:JAN]'s compliance with Metoclopramide hydrochloride [USAN:JAN] specifications and serves as a tool for batch-level quality control.
Metoclopramide hydrochloride [USAN:JAN] CoA mostly includes findings from lab analyses of a specific batch. For each Metoclopramide hydrochloride [USAN:JAN] CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Metoclopramide hydrochloride [USAN:JAN] may be tested according to a variety of international standards, such as European Pharmacopoeia (Metoclopramide hydrochloride [USAN:JAN] EP), Metoclopramide hydrochloride [USAN:JAN] JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Metoclopramide hydrochloride [USAN:JAN] USP).